157 related articles for article (PubMed ID: 36245978)
21. Comprehensive Analyses of MELK-Associated ceRNA Networks Reveal a Potential Biomarker for Predicting Poor Prognosis and Immunotherapy Efficacy in Hepatocellular Carcinoma.
Liu Y; Li R; Wang X; Xue Z; Yang X; Tang B
Front Cell Dev Biol; 2022; 10():824938. PubMed ID: 35693941
[No Abstract] [Full Text] [Related]
22. UHRF1 Could Be a Prognostic Biomarker and Correlated with Immune Cell Infiltration in Hepatocellular Carcinoma.
Li D; Chen B; Zeng Y; Wang H
Int J Gen Med; 2021; 14():6769-6776. PubMed ID: 34675635
[TBL] [Abstract][Full Text] [Related]
23. High expression of CCDC6 in relation to unfavorable outcome and immune cells infiltration in hepatobiliary carcinoma.
Wu T; Jiang X; Xu B; Zhong Q; Zheng J; Zhang X; Wang Y
J Cancer; 2022; 13(12):3378-3395. PubMed ID: 36186907
[No Abstract] [Full Text] [Related]
24. CSTF2 Acts as a Prognostic Marker Correlated with Immune Infiltration in Hepatocellular Carcinoma.
Zhang W; Wan Y; Zhang Y; Liu Q; Zhu X
Cancer Manag Res; 2022; 14():2691-2709. PubMed ID: 36117731
[TBL] [Abstract][Full Text] [Related]
25. STING pathway contributes to the prognosis of hepatocellular carcinoma and identification of prognostic gene signatures correlated to tumor microenvironment.
Pu Z; Liu J; Liu Z; Peng F; Zhu Y; Wang X; He J; Yi P; Hu X; Fan X; Chen J
Cancer Cell Int; 2022 Oct; 22(1):314. PubMed ID: 36224658
[TBL] [Abstract][Full Text] [Related]
26. RAB6B is a potential prognostic marker and correlated with the remolding of tumor immune microenvironment in hepatocellular carcinoma.
Peng H; Zhu E; Wang J; Du X; Wang C; Yang M; Zhang Y
Front Pharmacol; 2022; 13():989655. PubMed ID: 36120364
[No Abstract] [Full Text] [Related]
27. Prefoldin and prefoldin-like complex subunits as predictive biomarkers for hepatocellular carcinoma immunotherapy.
Zhao H; Chen C; Yang C; Mo S; Zhao H; Tian Y
Pathol Res Pract; 2022 Apr; 232():153808. PubMed ID: 35217267
[TBL] [Abstract][Full Text] [Related]
28. Identification of immune infiltration-related genes as prognostic indicators for hepatocellular carcinoma.
Dai K; Liu C; Guan G; Cai J; Wu L
BMC Cancer; 2022 May; 22(1):496. PubMed ID: 35513781
[TBL] [Abstract][Full Text] [Related]
29. Immune infiltration-associated serum amyloid A1 predicts favorable prognosis for hepatocellular carcinoma.
Zhang W; Kong HF; Gao XD; Dong Z; Lu Y; Huang JG; Li H; Yang YP
World J Gastroenterol; 2020 Sep; 26(35):5287-5301. PubMed ID: 32994688
[TBL] [Abstract][Full Text] [Related]
30.
Gao Y; Li Y; Song Z; Jin Z; Li X; Yuan C
J Oncol; 2022; 2022():6509028. PubMed ID: 35847356
[TBL] [Abstract][Full Text] [Related]
31. High RPS3A expression correlates with low tumor immune cell infiltration and unfavorable prognosis in hepatocellular carcinoma patients.
Zhou C; Weng J; Liu C; Zhou Q; Chen W; Hsu JL; Sun J; Atyah M; Xu Y; Shi Y; Shen Y; Dong Q; Hung MC; Ren N
Am J Cancer Res; 2020; 10(9):2768-2784. PubMed ID: 33042616
[TBL] [Abstract][Full Text] [Related]
32. Development and Validation of a Novel Ferroptosis-Related Gene Signature for Prognosis and Immunotherapy in Hepatocellular Carcinoma.
Zhang B; Zhao J; Liu B; Shang Y; Chen F; Zhang S; He J; Fan Y; Tan K
Front Mol Biosci; 2022; 9():940575. PubMed ID: 35847985
[TBL] [Abstract][Full Text] [Related]
33. CPNE1 is a potential prognostic biomarker, associated with immune infiltrates and promotes progression of hepatocellular carcinoma.
Su J; Huang Y; Wang Y; Li R; Deng W; Zhang H; Xiong H
Cancer Cell Int; 2022 Feb; 22(1):67. PubMed ID: 35139863
[TBL] [Abstract][Full Text] [Related]
34. NXPH4 Used as a New Prognostic and Immunotherapeutic Marker for Muscle-Invasive Bladder Cancer.
Gui Z; Ying X; Liu C
J Oncol; 2022; 2022():4271409. PubMed ID: 36245981
[TBL] [Abstract][Full Text] [Related]
35. PRRC2A Promotes Hepatocellular Carcinoma Progression and Associates with Immune Infiltration.
Liu X; Zhang Y; Wang Z; Liu L; Zhang G; Li J; Ren Z; Dong Z; Yu Z
J Hepatocell Carcinoma; 2021; 8():1495-1511. PubMed ID: 34881207
[TBL] [Abstract][Full Text] [Related]
36. Integrative Transcriptomic, Proteomic and Functional Analysis Reveals ATP1B3 as a Diagnostic and Potential Therapeutic Target in Hepatocellular Carcinoma.
Lu S; Cai S; Peng X; Cheng R; Zhang Y
Front Immunol; 2021; 12():636614. PubMed ID: 33868261
[TBL] [Abstract][Full Text] [Related]
37. Identification of the Tumor Immune Microenvironment and Therapeutic Biomarkers by a Novel Molecular Subtype Based on Aging-Related Genes in Hepatocellular Carcinoma.
Cai D; Zhao Z; Hu J; Dai X; Zhong G; Gong J; Qi F
Front Surg; 2022; 9():836080. PubMed ID: 35392063
[TBL] [Abstract][Full Text] [Related]
38. Identification of KRBA1 as a Potential Prognostic Biomarker Associated with Immune Infiltration and m6A Modification in Hepatocellular Carcinoma.
Liu Y; Fu B; Yu Z; Song G; Zeng H; Gong Y; Ding Y; Huang D
J Hepatocell Carcinoma; 2022; 9():497-516. PubMed ID: 35669909
[TBL] [Abstract][Full Text] [Related]
39. NXPH4 Promotes Gemcitabine Resistance in Bladder Cancer by Enhancing Reactive Oxygen Species and Glycolysis Activation through Modulating NDUFA4L2.
Wang D; Zhang P; Liu Z; Xing' Y; Xiao Y
Cancers (Basel); 2022 Aug; 14(15):. PubMed ID: 35954445
[TBL] [Abstract][Full Text] [Related]
40. Correlation of zinc finger protein 2, a prognostic biomarker, with immune infiltrates in liver cancer.
Sun L; Lin Y; Wang G; Zhang L; Hu L; Lu Z
Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33439969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
